×
June 23, 2016 by AutoCruitment

Bethany Bray, Chief Executive Officer and Co-Founder of AutoCruitment will be a featured presenter and panelist at the DIA Annual Meeting in Philadelphia.

ATLANTA, GA – June 23, 2016: Bethany Bray, Chief Executive Officer and Co-Founder of AutoCruitment will be a featured presenter and panelist at the DIA Annual Meeting in Philadelphia, PA. Drug Information Association (DIA) is the only global forum for knowledge exchange that fosters innovation to raise the level of health and well-being worldwide and has become an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation.

The session entitled “Patient Recruitment in Rare Diseases: Ideas and Framework for out-of-the-Box Exploration”, will explore the challenges of recruiting patient participants in clinical studies involving rare diseases where populations are small and geographically dispersed. The aim of the session is to “catalyze unconventional thinking, judge industry leaders various recruitment strategies and to provide a framework to organize innovative recruitment ideas.” The discussion will focus on patient recruitment, retention, engagement and clinical trial designs.

Bethany’s initial presentation, “Direct-to-Patient Digital Recruitment: A Targeted Approach to Recruitment Enrollment and Retention”, addresses how digital marketing techniques can be used to recruit, control and retain enrolled participants in clinical trials. An Oncology and Neuroscience Researcher, Entrepreneur and Technologist, Bethany founded AutoCruitment to fulfill a vision of utilizing the power of the internet to address recruitment, enrollment and retention problems in clinical trials.

AutoCruitment is able to provide a path to effective digital marketing presence through a proprietary and targeted, direct-to-patient, online marketing platform that targets, recruits, screens and automatically refers new patients for clinical trials or specialty medical procedures. By streamlining the recruitment process, AutoCruitment helps accelerate the commercialization of safe, effective new treatments for devastating diseases and conditions and directs patients to new and suitable providers.

Bray has 10 years of experience in Pharmaceutical Research, Operations and Business Development and holds a BSc in Pharmacology, a Masters in Translational Medicine & Neuroscience from Imperial College London and an MBA from the Georgia Institute of Technology.

For more information on the DIA 2016 Annual Meeting and Conference and how you can participate click on http://www.diaglobal.org

About AutoCruitment

AutoCruitment is an industry leader in clinical trial patient recruitment, offering online recruitment services and use of the web-based AutoCruitment Platform globally.

AutoCruitment was founded in 2014 by Bethany Bray, MBA MRes (Imperial College London), Ben Cooper and Chris Klaus (founder of Internet Security Systems; now part of the IBM Group). The leading, web-based recruitment company is headquartered in Technology Square, Atlanta GA with Project Management and Operations located in New York, NY and Toronto, ON.

AutoCruitment has assisted in the recruitment and automated screening of patients for all therapeutic areas and is currently working with 4 of the top 10 pharmaceutical companies, 9 of the largest CROs worldwide, numerous hospitals and research sites to reduce the time it takes to get lifesaving therapies to market; through the use of their platform which recruits and matches qualified patients to the correct trials and clinical programs, automatically.

AutoCruitment’s targeted, metrics-driven approach and web-based technology closes the enrollment gap and accelerates patient recruitment by an average of 72%.

June 23, 2016 , by AutoCruitment

 

Never Miss Any News

Join our community and get notified of any new articles.

If you enjoyed this AutoCruitment article,
you'll probably like

AutoCruitment’s patient recruitment platform supports Sponsors, CRO Partners and Research Sites by decreasing time,
risk and cost to bring new therapies to market.

Contact Us